As of January 22, 2025, Contineum Therapeutics (CTNM) has a market cap of $0.29 billion USD. According to our data, Contineum Therapeutics is ranked No.6747 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.29 B |
3.55%
|
Dec 31, 2024 | $0.28 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Precision BioSciences
DTIL
|
$38.13 M |
0.000 M
|
USA
|
Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
REGENXBIO
RGNX
|
$0.39 B |
-0.000 M
|
USA
|
Voyager Therapeutics
VYGR
|
$0.30 B |
-0.000 M
|
USA
|
Market Cap | = | CTNM Stock Price | * | CTNM Shares Outstanding |
= | $11.21 | * | 19.05 M | |
= | $0.29 B |